OTCM
VIMGF
Market cap2.03bUSD
Jan 09, Last price
2.45USD
Name
Vimian Group AB
Chart & performance
P/E
36.67
P/S
2.70
EPS
0.06
Vol. 1Y
—
Shs. 5Y
6.89%
Rev. 5Y
25.27%
Div Yld LY
—
Div Yld TTM
—
Revenues
425m
+13.39%
Net income
31m
+69.19%
CFO
106m
+81.93%
Earnings
Oct 22, 2026
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vimian Group AB (publ) is an international enterprise focused on the animal health sector, organized into four distinct divisions: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers a range of proprietary diagnostic tools and treatments under its Nextmune brand, providing both prescription and non-prescription options for the preventive care and management of chronic conditions in companion animals. Through its Indical Bioscience brand, Vimian delivers sophisticated molecular and immunodiagnostic solutions for laboratories, specifically targeting veterinary applications for both livestock and companion animal health markets. Moreover, its VetFamily brand operates a membership-based platform that provides veterinary clinics with procurement services, tech-enabled operations including online marketing, education, and HR support, as well as a professional community. The company also supplies orthopedic implants to veterinarians and universities through its Movora brand. Established in 2020, Vimian Group is based in Stockholm, Sweden.
Related entities
Parent (2)
Fidelio Vet Holding AB
Berghamnen AB
Subsidiaries
Vimian FinCo AB
Key people
Independent Chairman of the Board · since 2024
Patrik Eriksson
Chief Executive Officer · since 2024
Carl-Johan Boudrie
Chief Financial Officer · since 2025
Magnus Kjellberg
Chief Executive Officer, Nextmune · since 2017
Stefano Santarelli
Chief Executive Officer, Indical Bioscience · since 2021
Guy Spoerri
Chief Executive Officer, Movora · since 2023
Alireza Tajbakhsh
Chief Executive Officer · since 2025
Carl-Johan Ehn
General Counsel · since 2022
Martin Bengtson
Head of Mergers and Acquisition · since 2021
Theodor Bonnier
Non-Executive Director · since 2021
Gabriel Fitzgerald
Non-Executive Director · since 2024
Non-Executive Independent Director · since 2022
Headquarters & legal address
Riddargatan 19
Stockholm, AB 114 57
SE
Stockholm, AB 114 57
SE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||